Drug Profile
Ainuovirine - Kainos Medicine
Alternative Names: ACC-007; Aibangde; Einovirine; iBond; KM-023Latest Information Update: 27 Sep 2022
Price :
$50
*
At a glance
- Originator Kainos Medicines
- Developer Jiangsu Aidea Pharmaceutical; Kainos Medicines
- Class Antiretrovirals
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HIV infections
Most Recent Events
- 27 Sep 2022 KM 23 is still in phase-III trials for HIV infections in unknown Country (http://kainosmedicine.com/?c=user&mcd=eng03_01)
- 28 May 2020 Phase-III clinical trials in HIV infections (PO), prior to May 2020 (Kainos Medicine website, May 2020)
- 28 May 2020 Pharmacodynamics data from preclinical trials in HIV infections released by Kainos Medicine (Kainos Medicine website, May 2020)